compound introduction
Information GSK3145095 GSK3145095 is a potent and orally active RIP1 kinase inhibitor with IC50 of 6.3 nM with potential antineoplastic and immunomodulatory activities. Targets RIP1 kinase (Cell-free assay) 6.3 nM In vitro GSK3145095 potently binds to RIP1 with exquisite kinase specificity and has excellent activity in blocking RIP1 kinasedependent cellular responses. Highlighting its potential as a novel cancer therapy, the inhibitor is also able to promote a tumor suppressive T cell phenotype in pancreatic adenocarcinoma organ cultures. Cell Research(from reference) Cell lines：U937 cells, L-cells NCTC 929 (L929) cells Concentrations：0-3 μM Incubation Time：5 h
